Northrim BanCorp (NASDAQ:NRIM) declared a regular quarterly cash dividend of $0.16 per share on Monday, maintaining its payout level as it caps off a year of significant expansion in its loan portfolio and specialty finance operations.
US Democratic senators filed a series of ethics-focused amendments to the crypto market structure bill as part of a broader effort to curb potential conflicts of interest tied to digital assets.
ByteDance has struck a definitive agreement to restructure TikTok’s American operations into a majority U.S.-owned joint venture, a move that effectively ends a six-year geopolitical tug-of-war over the social media giant’s presence in the United States.
Northrim BanCorp (NASDAQ:NRIM), the parent company of Northrim Bank, reported strong financial results for the fourth quarter and full year ended December 31, 2025.
Janus Henderson Group (NYSE:JHG) is making a major play for the fast-growing model portfolio market, announcing Friday its acquisition of Richard Bernstein Advisors (RBA), a New York-based firm overseeing approximately $20 billion in assets.
Bausch Health Companies (NYSE:BHC) today announced results from its global Phase 3 RED-C clinical program evaluating amorphous-rifaximin SSD for the primary prevention of hepatic encephalopathy (HE) in adults with liver cirrhosis.
Sanara MedTech (NASDAQ:SMTI) announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, along with initial guidance for 2026.
Webster Financial (NYSE:WBS), the holding company for Webster Bank, reported strong financial results for the fourth quarter ended December 31, 2025.
Osisko Development (NYSE:ODV0 has temporarily suspended activities at its Cariboo Gold Project in central British Columbia after a contractor suffered a fatal injury at the site.
OKYO Pharma (NASDAQ:OKYO) announced that the U.S. Food and Drug Administration has authorized a single-patient expanded access Investigational New Drug application (IND 176297) for urcosimod 0.05% to treat a patient with severe neuropathic corneal pain (NCP).
ImmunityBio (NASDAQ:IBRX) reported updated Phase 2 clinical results for its novel immunotherapy combination in patients with recurrent glioblastoma, suggesting the treatment may overcome the "immune collapse" that typically follows standard cancer therapies.
SLB (NYSE:SLB) today reported financial results for the fourth quarter and full year ended December 31, 2025, reflecting sequential improvement driven by international activity and offshore growth despite softer year-over-year comparisons.
